Premium
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
Author(s) -
Cusi K.,
Sanyal A. J.,
Zhang S.,
Hoogwerf B. J.,
Chang A. M.,
Jacober S. J.,
BueValleskey J. M.,
Higdon A. N.,
Bastyr E. J.,
Haupt A.,
Hartman M. L.
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12751
Subject(s) - insulin glargine , medicine , endocrinology , insulin , basal (medicine) , type 1 diabetes , type 2 diabetes , gastroenterology , diabetes mellitus , hypoglycemia
Aims To compare effects of basal insulin peglispro ( BIL ), a hepatopreferential insulin, to insulin glargine (glargine) on aminotransferases and liver fat content ( LFC ) in patients with type 1 and type 2 diabetes ( T1D , T2D ). Materials and Methods Data from two Phase 2 and five Phase 3 randomized trials comparing BIL and glargine in 1709 T1D and 3662 T2D patients were integrated for analysis of liver laboratory tests. LFC , measured by magnetic resonance imaging ( MRI ) at baseline, 26 and 52 weeks, was analyzed in 182 T1D patients, 176 insulin‐naïve T2D patients and 163 T2D patients previously treated with basal insulin. Results Alanine aminotransferase ( ALT ) increased in patients treated with BIL , was higher than in glargine‐treated patients at 4‐78 weeks (difference at 52 weeks in both T1D and T2D : 7 international units/litre ( IU /L), P < .001), and decreased after discontinuation of BIL . More BIL patients had ALT ≥ 3× upper limit of normal ( ULN ) than glargine. No patient had ALT ≥ 3× ULN with bilirubin ≥ 2× ULN that was considered causally related to BIL . In insulin‐naїve T2D patients, LFC decreased with glargine but was unchanged with BIL . In T1D and T2D patients previously treated with basal insulin, LFC was unchanged with glargine but increased with BIL . In all three populations, LFC was higher after treatment with BIL vs glargine (difference at 52 weeks: 2.2% to 5.3%, all P < .01). Conclusions Compared to glargine, patients treated with BIL had higher ALT and LFC at 52‐78 weeks. No severe drug‐induced liver injury was apparent with BIL treatment for up to 78 weeks.